Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
about
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaTreatment of relapsed and refractory multiple myelomaMonoclonal antibodies targeting CD38 in hematological malignancies and beyondSelection and expansion of natural killer cells for NK cell-based immunotherapyHuman NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 ReceptorMechanisms of action of therapeutic antibodies for cancerDaratumumab: First Global Approval.A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.Therapeutic potential and challenges of natural killer cells in treatment of solid tumorsNatural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.The safety of daratumumab for the treatment of multiple myeloma.Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Immunotherapies targeting CD38 in Multiple Myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionModeling Natural Killer Cell Targeted Immunotherapies.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.Antibody based immunotherapy for multiple myeloma: it's about time.Tumor immunotherapy: New aspects of natural killer cells.Next generation immune-checkpoints for cancer therapy.CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceLenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
P2860
Q26745919-5D97409C-31EC-4C19-82FA-638B1ACB7DE6Q26749180-B5AA4918-54CC-4D15-B1C5-75F9A69A26BEQ26766718-0CD85D77-C050-4163-B06C-A8D49B1D9D4FQ26774777-CBC10A29-6726-4C1E-86AB-DFD3100AFFD7Q28067468-919617A1-DB5A-4AAE-BC94-8DE3561BF86FQ28385366-EC999762-C90E-47C4-AFF5-BD8F399956ABQ34507354-E22CE418-3A75-451D-8669-68742E6934F4Q36070261-79560B86-3331-4438-9D0E-68AD3D70612CQ38478878-94F85B1A-7A03-4918-831B-1ED4DDA6573CQ38542034-37B67B0D-83ED-4609-9E13-3F337533DBD4Q38737970-9782CE15-19DB-4E08-B00F-A4E5049529AFQ38745915-BA7A25ED-F0E6-4807-AF7E-1169418EE06AQ38793959-679AA167-5473-4CDC-BC58-E274FC94B901Q38809499-0254200B-7677-4239-BF73-D2153F0B88BDQ38820002-62B8CF9F-E53E-4595-9BB6-FD74E4940BF3Q39045031-5CE48D69-DB72-4F1C-9F61-B81DC1EEE3EDQ39100317-BD9BFD57-1F19-4D0A-8883-9F206FEDDADEQ39136762-50311412-2FE6-4D7C-A6F3-F2E50D336AEDQ39239278-B702B2E8-9740-48FA-AD5D-18956CF6E4EEQ42042886-423C5449-7080-441E-998C-DDF74A9ADBB2Q47203479-27AF1F56-9730-42DF-8307-1E7FBF4F12CBQ47660573-3A7B65DD-4C69-486C-9BF4-D31025B53484Q49830211-5AC1049B-B6D1-41C4-B9EF-C85A6DD4E931Q52615722-1BF60C1B-9E98-4F1C-8A3D-DC03399F349EQ53349911-9A3F8BAA-73A1-4F50-B3DB-15719C54A65EQ55107050-B98A15AF-BE56-448F-97EB-4B7C1F82FBBEQ55383705-695ED371-1925-4F81-B0F0-0E768E100123Q57191729-A5EADF4C-5A85-4EDC-A555-651C5998C58AQ58552961-05E01679-3D83-4056-A235-35C76FABC12C
P2860
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.
@en
Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.
@nl
type
label
Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.
@en
Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.
@nl
prefLabel
Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.
@en
Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.
@nl
P2093
P2860
P1433
P1476
Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.
@en
P2093
Berris van Kessel
Henk M Lokhorst
Inger S Nijhof
Jeroen J Lammerts van Bueren
Niels W C J van de Donk
Pascale Andre
Tuna Mutis
Yannis Morel
P2860
P304
P356
10.3324/HAEMATOL.2014.117531
P577
2014-12-15T00:00:00Z